This issue of the journal features an interesting and timely debate on the consequences, both actual and potential, of the various expedited drug approval programs that have been introduced over the past 20 years at the US Food and Drug Administration (FDA). Wallach, Ross and Naci, in addition to describing the distinctive features of the various programs, present opinions on their strengths and weaknesses and make some suggestions for improvement. Detailed commentaries are provided by Robert Califf, Janet Woodcock and Richard Schilsky. Their commentaries encompass many critical contemporary issues and controversies regarding the design of clinical trials and their central role in establishing the evidence basis for drug approvals and for continued post-marketing evaluation of their efficacy and side effects. A number of themes emerge.
First, has the introduction of these expedited programs been a positive change? Wallach et al. seem skeptical, arguing that there has been a slippage of the rigor of evidence required for drug approvals. All three commentators disagree with the central premise that expedited programs have had an overall negative impact. The commentators broadly posit that the landscape has changed in fundamental ways that require significant modifications of the approval process. These include, prominently, the vastly increased role of patient activism and the increasing development of niche drugs that target much smaller patient populations. Interestingly, very little mention is made of the political pressure that has been placed on the FDA to be more industry-friendly, a force that seems to us to have been a very important impetus for the evolution of the FDA approval standards.
Several details of the approval system draw contrasting opinions. Randomization has played a very prominent role historically, through the traditional (but not absolute) requirement of two pivotal randomized trials demonstrating statistically significant evidence of efficacy. An increasing number of drugs, particularly drugs for treatment of cancer, are now approved based on evidence from relatively small, non-randomized trials. Wallach et al. lament this development as a major retreat from scientific rigor. Califf takes care to point out that he supports the need for randomization but advocates for the use of more creative study designs, such as pragmatic trials that could in principle involve cluster randomization or other recent innovations. Woodcock and Schilsky, on the other hand, while acknowledging the importance of randomization, focus on the rationale for trends to eliminate the requirement for randomized evidence in some areas. Schilsky in particular argues that the frequently high response rates of targeted agents, together with the strong biological plausibility arising from the fact that the drugs are specifically designed for certain tumor mutations, may reduce the need for randomized evidence. Schilsky also notes the difficulty of doing comparative trials in the smaller populations with the specific targeted tumor type. Although we recognize that there are cases where initial findings even in uncontrolled studies are so strong that randomized trials may be unnecessary, we share the concern of Wallach and colleagues that this kind of thinking could put us on a slippery slope. We have had serious problems in the past, such as excessive enthusiasm for the highly toxic regimen of high-dose therapy with bone marrow transplantation for breast cancer in the 1990s that raised resistance to the conduct of randomized trials, but for which no advantage was demonstrated when randomized trials were finally completed. In fact, early evidence of high response rates should actually make randomized trials much shorter.
Another contentious issue is the use of surrogate endpoints (biomarkers). Wallach et al. believe that there should be strict standards for validating biomarkers for use in the context of drug approvals. Califf seems to agree, expressing skepticism about the broad use of surrogate endpoints, while Woodcock and Schilsky are more positive about using markers to support drug approval.
The status of post-marketing studies is the only issue that seems to enjoy consensus from Wallach et al. and all three commentators. There is general agreement that the conduct of these studies is frequently inadequate. They can fail to address the various questions that are important after approval, such as the risks of longerterm side effects and the need for more definitive efficacy results following an initial approval based on nonrandomized evidence and/or the use of surrogate endpoints. The concept of using real-world evidence as a source of information is addressed by all the authors but there is a lack of consistency regarding what the different authors mean by this term. Califf clarifies that use of real-world evidence should not encompass results from observational studies of databases that were not constructed prospectively with a careful design to address a precise scientific goal. His concept is to harness existing electronic resources to conduct carefully designed controlled studies in conventional clinical settings, that is, using in essence pragmatic clinical trials.
The fundamental axis that separates the various opinions concerns the strength of evidence that should be required before a drug is marketed. Wallach et al. appear to favor the strict standards that governed approvals until the era of expedited approvals, while Schilsky and Woodcock in particular believe that we need to trade-off some of this strength of evidence, at least in some circumstances, in order to get promising new agents to the public more rapidly. What strength of evidence should be required, and how much flexibility should there be for different contexts? The answer to this crucial question is necessarily both subjective and arbitrary. Clearly, the less evidence required, the greater the risk that an ineffective or even harmful agent will be marketed, with the resulting downstream negative impact on the public health. A problematic concern is that as evidentiary standards for drug approval are lowered, the need for carefully designed and credible postmarketing studies becomes increasingly important. However, all three commentators note that postmarketing research is a problematic issue. When the FDA approves a drug for marketing, they may render it ethically questionable to subsequently conduct randomized trials that can address the issue of efficacy convincingly. In other words, rigorous post-marketing research is inherently challenging and it cannot fully compensate for the kind of evidence that can only be assembled in the pre-marketing setting. Some efforts have been made in the evaluation of new drugs to treat type 2 diabetes, where the current standard is to allow approval based on control of HbA1C, but to have trials continue until effects on cardiovascular outcomes can be assessed and unacceptable risks ruled out. It is not at all clear, however, that such a model could work in cancer, where an early positive finding based on a marker or response rate would likely preclude trial continuation with those initially assigned to the control regimen expected to remain on that regimen. So, in our opinion, the issue really boils down to the appropriate strength of evidence required for marketing approval. The commentators, Schilsky and Woodcock especially, argue that patients with serious diseases are willing to take the greater risks to obtain early access and that this justifies a less rigorous standard of evidence. Again we feel that caution is needed when pursuing this line of thinking. In the long history of clinical research, countless agents have appeared promising based on limited evidence, only to lead to ultimate disappointment. The requirement of rigorous evaluation of new drugs, pursued diligently by the FDA, often under extraordinary external pressures, has been a crucial tool to protect the public health by ensuring that marketed agents are effective and acceptably safe. While we must allow for circumstances in which rapid approval based on marker or early clinical results in uncontrolled studies is justified, the gradual unwinding of this system without great care to ensure that the needed scientific evidence is preserved would ultimately be damaging to the very people most in need of effective drugs.
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